The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions early access to medicines that show early signs of having a major advantage over existing therapeutics.
Similar Posts
Professor Richard FitzGerald appointed to the Commission on Human Medicines
The appointment will involve a time commitment of approximately 22 days per year including 11 meetings. Remuneration for the roles will be at a rate of £325 per meeting.
Supplying authorised medicines to Northern Ireland
What you need to do to supply authorised medicines from Great Britain to Northern Ireland.
Corporate report: Medicines and Healthcare Products Regulatory Agency Annual Report and Accounts 2024 to 2025
MHRA annual report and accounts 2024 to 2025.
Class 4 Medicines Defect Notification: Ipca Laboratories UK Limited, Various Products, EL(25)A/42
Ipca Laboratories UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.
Strengthening collaboration between the MHRA and the Department of Health Northern Ireland
The MHRA and Northern Ireland partners are working together to support innovation, enhance patient safety and ensure people in Northern Ireland benefit from world-class regulation.
Types of application for marketing authorisations (legal basis of applications)
You must include the appropriate legal basis for your application when you apply to MHRA for a marketing authorisation.